Form 4: STERIS plc Executive Sells Shares in Recent Transaction

Cary L. Majors, SVP and President of Healthcare at STERIS plc, sold 1,682 ordinary shares at an average price of $217.32 per share on November 25, 2024.

Summary

• Cary L. Majors, a Senior Vice President and President of Healthcare at STERIS plc, sold 1,682 ordinary shares of the company on November 25, 2024.
• The sale was executed at a weighted average price of $217.32 per share, with individual transaction prices ranging from $217.32 to $217.40.
• Following the transaction, Mr. Majors directly owns 11,372 ordinary shares and indirectly owns 67 ordinary share equivalents through the STERIS Corporation 401(k) Plan.
• Of the directly owned shares, 9,872 are restricted and will vest over time, with the first tranche of 1,964 shares vesting on June 2, 2025.

Sentiment

Score: 5

Explanation: The document is a neutral report of an insider transaction. It doesn't indicate positive or negative sentiment about the company's performance or future prospects.

Industry Context

This is a routine disclosure of an insider transaction, which is common for publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The sale of shares by an executive is a common occurrence and does not necessarily indicate a negative outlook for the company.
• Similar filings can be seen across the healthcare and medical device industry, with companies like Medtronic, Abbott, and Stryker regularly reporting insider transactions.

Stakeholder Impact

• The share sale by an executive may have a minor impact on shareholder sentiment, but it is a routine transaction.
• The vesting schedule of restricted shares may be of interest to shareholders.

Key Dates

Keywords

STERIS plc, insider trading, share sale, executive, Cary L. Majors, stock transaction, restricted shares, Form 4